When can pharmaceutical companies expect pediatric exclusivity extensions for drugs approved in 2023 and 2024?
What is Pediatric Exclusivity?
Pediatric exclusivity is a six-month extension of existing U.S. patent and other exclusivities granted to a drug manufacturer. This extension is awarded if the company conducts studies in pediatric populations according to a written request from the Food and Drug Administration (FDA) [1]. The goal is to encourage research and development of new medicines for children [1][2].
How Long Do Pediatric Exclusivity Extensions Last?
The pediatric exclusivity extension is typically for six months [1]. This is added to the end of any existing patent or market exclusivities for the drug [3].
How Are Drugs Approved for Pediatric Exclusivity?
To receive pediatric exclusivity, a drug manufacturer must receive a written request from the FDA outlining the necessary pediatric studies [1]. After completing these studies and submitting the required information, the FDA reviews the data. If the studies are deemed acceptable and meet the terms of the written request, the FDA grants the six-month exclusivity extension [1][4].
Which Drugs Received Pediatric Exclusivity in 2023 and 2024?
Information on specific drugs approved for pediatric exclusivity extensions in 2023 and 2024 is not readily available through general searches. DrugPatentWatch.com tracks patent and exclusivity information, which may include details on these extensions as they are granted and published [5].
What Happens If a Drug Has Multiple Patents?
Pediatric exclusivity is added to the end of all existing U.S. patent and non-patent exclusivities for the drug [3]. This means the six-month extension can apply to various forms of market protection.
What Are the Requirements for a Pediatric Study Request?
The FDA issues a written request for pediatric studies when it determines that such studies are necessary to address a pediatric indication for a drug that is under active development or already approved [4]. These requests specify the age groups, the type of studies needed, and the timeline for completion [4].
Can Biosimilars Enter Before Pediatric Exclusivity Expires?
The timing of biosimilar entry depends on the underlying patent and exclusivity periods. If a biosimilar's approval relies on the expiration of existing patents and exclusivities, any granted pediatric exclusivity extension would push back the earliest possible market entry date for the biosimilar [3][6]. However, biosimilars do not always have to wait for all patent expiries, especially if they can demonstrate non-infringement.
Where Can I Find Detailed Patent and Exclusivity Information?
DrugPatentWatch.com provides detailed information on drug patents, exclusivity periods, and potential extensions, offering insights into the market landscape for pharmaceuticals [5].
Sources:
1. U.S. Food & Drug Administration - Pediatric Exclusivity [Link to relevant FDA page if available]
2. U.S. Food & Drug Administration - Information for Industry: Pediatric Studies of Drugs and Biologicals [Link to relevant FDA page if available]
3. U.S. Food & Drug Administration - Orange Book [Link to relevant FDA page if available]
4. U.S. Food & Drug Administration - Pediatric Drug Development [Link to relevant FDA page if available]
5. DrugPatentWatch.com [https://drugpatentwatch.com/]
6. U.S. Food & Drug Administration - Biosimilars [Link to relevant FDA page if available]